citalopram has been researched along with Attention Deficit and Disruptive Behavioral Disorders in 3 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Carlson, GA | 1 |
| Klein, DN | 1 |
| Towbin, K | 1 |
| Vidal-Ribas, P | 1 |
| Brotman, MA | 1 |
| Pickles, A | 1 |
| Miller, KV | 1 |
| Kaiser, A | 1 |
| Vitale, AD | 1 |
| Engel, C | 1 |
| Overman, GP | 1 |
| Davis, M | 1 |
| Lee, B | 1 |
| McNeil, C | 1 |
| Wheeler, W | 1 |
| Yokum, CH | 1 |
| Haring, CT | 1 |
| Roule, A | 1 |
| Wambach, CG | 1 |
| Sharif-Askary, B | 1 |
| Pine, DS | 1 |
| Leibenluft, E | 1 |
| Stringaris, A | 1 |
| Hilton, RC | 1 |
| Rengasamy, M | 1 |
| Mansoor, B | 1 |
| He, J | 1 |
| Mayes, T | 1 |
| Emslie, GJ | 1 |
| Porta, G | 1 |
| Clarke, GN | 1 |
| Wagner, KD | 1 |
| Birmaher, B | 1 |
| Keller, MB | 1 |
| Ryan, N | 1 |
| Shamseddeen, W | 1 |
| Asarnow, JR | 1 |
| Brent, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Controlled Trial of Citalopram Added to Methylphenidate in Youth With Severe Mood Dysregulation[NCT00794040] | Phase 2 | 103 participants (Actual) | Interventional | 2008-11-17 | Completed | ||
| Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)[NCT00018902] | Phase 2/Phase 3 | 334 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"A measure of change of irritability severity taking the baseline before randomization as a reference. Scores range 1 to 8, in which 1=Completely recovered,... 5=Unchanged,... 8=Much worse.~Percentage of participants who responded are based on an estimation and might not match exactly with discrete numbers of participants based on the denominator." (NCT00794040)
Timeframe: Collected weekly during the 8-week trial. The 8th-week outcome is reported.
| Intervention | estimated percentage of participants (Number) |
|---|---|
| Add-on Citalopram Following Optimized Methylphenidate | 35 |
| Add-on Placebo Following Optimized Methylphenidate | 6 |
Difference in anxiety symptoms at 8th week of trial as measured with the Pediatric Anxiety Rating Scale (PARS) with scores ranging 0-25. Higher values represent a worse outcome. (NCT00794040)
Timeframe: Collected weekly during the 8th week trial. The 8th-week outcome is reported.
| Intervention | units on a scale (Mean) |
|---|---|
| Add-on Citalopram Following Optimized Methylphenidate | 12.0 |
| Add-on Placebo Following Optimized Methylphenidate | 13.4 |
Difference in depressive symptoms at 8th week of trial as measured with Children's Depression Rating Scale (CDRS) with scores ranging 17-113, where scores >40 are considered over the clinical threshold, and scores <28 are considered within the healthy range. (NCT00794040)
Timeframe: Collected weekly during the 8th week trial. The 8th-week outcome is reported.
| Intervention | units on a scale (Mean) |
|---|---|
| Add-on Citalopram Following Optimized Methylphenidate | 28.6 |
| Add-on Placebo Following Optimized Methylphenidate | 30.1 |
Difference in functional impairment at 8th week of trial as measured with Children's Global Impression Scale (CGAS) with scores ranging from 1=Most impaired to 100=Not impaired at all. (NCT00794040)
Timeframe: Collected weekly during the 8th week trial. The 8th-week outcome is reported.
| Intervention | units on a scale (Mean) |
|---|---|
| Add-on Citalopram Following Optimized Methylphenidate | 52.6 |
| Add-on Placebo Following Optimized Methylphenidate | 47.2 |
Clinical Global Impression-Severity (CGI-S): A measure of severity of irritability scale (from 1=Normal, not at all ill to 7=Among the most extremely ill patients). (NCT00794040)
Timeframe: Collected weekly during the 8th week trial. The 8th-week outcome is reported.
| Intervention | units on a scale (Mean) |
|---|---|
| Add-on Citalopram Following Optimized Methylphenidate | 3.1 |
| Add-on Placebo Following Optimized Methylphenidate | 3.9 |
2 trials available for citalopram and Attention Deficit and Disruptive Behavioral Disorders
| Article | Year |
|---|---|
A Double-Blind Randomized Placebo-Controlled Trial of Citalopram Adjunctive to Stimulant Medication in Youth With Chronic Severe Irritability.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Central Nervous System Stimulants; | 2020 |
Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.
Topics: Adolescent; Anxiety; Attention Deficit and Disruptive Behavior Disorders; Behavioral Symptoms; Cital | 2013 |
1 other study available for citalopram and Attention Deficit and Disruptive Behavioral Disorders
| Article | Year |
|---|---|
Editorial: Antidepressants to the Rescue in Severe Mood Dysregulation and Disruptive Mood Dysregulation Disorder?
Topics: Adolescent; Adult; Antidepressive Agents; Attention Deficit and Disruptive Behavior Disorders; Child | 2020 |